MedTrace Logo

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT06057948 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2026-04-02

No results posted yet for this study

Summary

The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.

Conditions

Interventions

BIOLOGICAL

OPT-821 (QS-21)

Comprised of the immunological adjuvant OPT-821 (QS-21)

DIETARY_SUPPLEMENT

oral β-glucan

Participants will be randomized to receive this agent in two different schedules

Sponsors & Collaborators

Principal Investigators

  • Brian Kushner, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2027-03-21
Completion
2027-03-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06057948 on ClinicalTrials.gov